NEW YORK (GenomeWeb) – Pressure Biosciences said today that is has completed the fourth closing of its $5 million private placement.

With the closing the company raised an additional $730,000, bring the total amount raised in the offering to nearly $4.8 million. It will issue senior secured debentures with a fixed conversion price of $.28 per restricted common share and common stock purchase warrants exercisable into a total of 1,303,571 shares of restricted stock at an exercise price of $.40 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.